AstraZeneca Partners With AmoyDx On Companion Diagnostics For Lynparza
Deal Snapshot: Teaming again with the Shanghai biotech, AstraZeneca will seek assays that can be incorporated into companion diagnostics for Lynparza in prostate and breast cancer.
You may also be interested in...
The US FDA expanded the use of FoundationOne Liquid CDx as a companion diagnostic for certain prostate cancer patients eligible for treatment with olaparib.
Lynparza has received the green light from the FDA for advanced prostate cancer, its fourth tumor type, and while it may not be the first PARP inhibitor to be approved for this indication, analysts are expecting the drug to lead the class.
The FDA placed a hold on the Phase II study of SRP-5051, which uses the company’s next-generation peptide conjugation technology, but Sarepta thinks it can address safety questions in short order.